https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-27 08:31:172023-09-27 09:13:484SC receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-27 08:31:172023-09-27 09:13:484SC receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA
https://www.optimumcomms.com/wp-content/uploads/2023/05/Acension_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-26 07:03:562023-09-26 07:03:56Acesion Pharma Closes Oversubscribed €45M Series B Financing Round
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-25 08:48:482023-09-25 08:48:484SC: Landmark RESMAIN study data presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-21 14:00:082023-09-22 11:55:49Novo Holdings advances antimicrobial resistance strategy with acquisition of Paratek Pharmaceuticals
https://www.optimumcomms.com/wp-content/uploads/2023/07/Leucid_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-21 09:03:552023-09-21 09:05:09Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR T-Cell Therapy LEU011
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-21 07:00:052023-09-21 14:24:32New cell therapy facility enters fight against chronic diseases
https://www.optimumcomms.com/wp-content/uploads/2023/06/Poolbeg_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-20 09:02:152023-09-20 09:02:15Poolbeg Pharma plc – Immunomodulator I Patent Portfolio Strengthened
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-19 08:37:502023-09-19 08:37:50Novo Holdings invests in innovative water treatment pioneer, HPNow, as part of €14m round
https://www.optimumcomms.com/wp-content/uploads/2023/02/FM_Logo_300px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-18 07:30:302023-09-18 07:30:30Futura Medical plc – Interim Results 2023
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-15 08:09:312023-09-15 08:09:314SC: RESMAIN study data to be presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-14 08:45:102023-09-14 08:45:10Glentra Capital, a new energy transition investment firm backed by large Danish investors, announces first close of EUR 443 million
https://www.optimumcomms.com/wp-content/uploads/2023/09/hervolution-final-pastel-white.png
1804
3664
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-13 08:44:132023-09-13 08:44:13HERVOLUTION Therapeutics appoints Moderna Co-Founder and MIT Professor Robert S. Langer as Chair of its Scientific Advisory Board
https://www.optimumcomms.com/wp-content/uploads/2023/06/Synaffix_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-13 08:40:262023-09-13 08:40:26ABL Bio Taps into Synaffix ADC Technology
https://www.optimumcomms.com/wp-content/uploads/2023/06/Poolbeg_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-13 07:10:312023-09-13 07:10:31Poolbeg Pharma plc – Interim results for the six months to 30 June 2023
https://www.optimumcomms.com/wp-content/uploads/2023/07/IO-Biotech.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-12 13:08:582023-09-12 13:08:58IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ariceum_Logo_300x180px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-07 08:12:262023-09-07 08:12:26Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancerWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
